This content is from: Premium Life Sciences Funds Continue to Struggle in 2022 Most were down by double-digits in the first quarter. By Stephen Taub April 18, 2022
This content is from: Premium Perceptive Posts Biggest Loss in Its History Joseph Edelman’s life sciences firm suffered a rare major setback last year. By Stephen Taub January 14, 2022
This content is from: Premium Hedge Funds Shun the Private Markets Previously active firms in the venture capital market haven’t made any new investments over the past month or two. By Stephen Taub May 27, 2022
This content is from: Premium Life Sciences Venture Investments Still Have a Pulse Several leading hedge funds specializing in life sciences and biopharma have been more active in the private markets this quarter. But overall volume is still way down from the highs. By Stephen Taub March 24, 2022
This content is from: Premium Healthcare Hedge Funds Are in Critical Condition Many suffered additional huge losses in April and are now down well over 50 percent from their peaks. By Stephen Taub May 11, 2022
This content is from: Premium After a Tough 2021, RTW is Still Bullish One of the hottest biopharma and life sciences funds in recent years is confident that it can rebound from last year’s setback. By Stephen Taub February 23, 2022
